Interaction of CDKN2A and Sun Exposure in the Etiology of Melanoma in the General Population  by Berwick, Marianne et al.
degradation of BIM in order to provide
melanoma cells with resistance to anoikis
(Akiyama et al., 2009). The CDK inhibitor
p21, another target of the miR-17 family
(Fontana et al., 2008), is repressed
transcriptionally by TBX2 and TBX3
transcription factors, which are frequently
amplified in melanoma and are down-
stream effectors of the MAPK pathway
(Bennett, 2008). Sprouty2 is a wild type
BRAF inhibitor that is targeted by miR-21
(Kwak et al., 2011). The downregulation
of Sprouty2 observed in melanoma has
been hypothesized as an alternative
mechanism responsible for the aberrant
activation of MAPK pathway besides
BRAF mutation (Tsavachidou et al.,
2004). It is noteworthy that the three
genes described above share a common
feature as antagonists of the MAPK path-
way. As the PI3K/AKT and the MAPK
pathways have been shown to cooperate
in melanomagenesis both in vitro and in
mouse models (Dankort et al., 2009;
Meier et al., 2007), it is tempting to
hypothesize that, in the context of PTEN
deletion, the deletion of PTENP1 might
be an alternative mechanism evolved by
the tumor to activate the MAPK pathway.
In this respect, it is worth noticing that
most of the cases showing both PTENP1
and PTEN deletion (71.4%) harbor wild-
type BRAF.
In conclusion, our data indicate that
the recently identified tumor suppressor
gene PTENP1 undergoes genomic dele-
tion in human melanoma. Our data also
suggest that PTENP1 deletion might be
advantageous for the tumor not only
because of its PTEN-related function
but also for PTEN-unrelated ones.
Supplementary material including de-
tailed experimental procedures (Sup-
plemental Text S3 and Supplementary
Tables S2 and S3) is available online.
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TO THE EDITOR
A major goal in cancer prevention is to
identify genetic and environmental risk
factors and determine if they interact to
increase risk. Melanoma is an excellent
model because intermittent sun expo-
sure is a well-supported environmental
risk factor for the development of mela-
noma and a genetic factor, CDKN2A,
has a major role in melanoma etiology.
We have sequenced CDKN2A, the majorAbbreviations: MPM, multiple primary melanoma; SPM, single primary melanoma
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n=1,207 ORcrude (95% CI) ORadjusted (95% CI)
1 P2 P3
UVE at age 10 (kJm2)
No mutation 303–912 1,230 463 1.00 1.00
913–2,084 1,042 643 1.64 (1.42, 1.89) 1.26 (0.95, 1.67)
Missing 167 66
With mutation 303–912 17 15 1.00 1.0
913–2,084 12 20 1.89 (0.69, 5.12) 1.18 (0.39, 3.54) 0.92 0.83
Missing 1 0
Sunny holiday—average hours per year
No mutation 0–19 1,013 406 1.00 1.00
20–678 969 454 1.17 (0.99, 1.37) 1.33 (1.11, 1.59)
Missing 457 312
With mutation 0–19 12 11 1.00 1.00
20–678 14 16 1.25 (0.42, 3.69) 0.92 (0.28, 2.99) 0.55 0.24
Missing 4 8
Beach and waterside activities—average hours per year
No mutation 0–24 1,203 570 1.00 1.00
25–1,857 1,164 575 1.04 (0.91, 1.20) 1.20 (1.02, 1.41)
Missing 72 27
With mutation 0–24 7 10 1.00 1.00
25–1,857 23 25 0.76 (0.25 2.33) 0.87 (0.26, 2.85) 0.59 0.41
Missing 0 0
Lifetime painful or blistering sunburns
No mutation 0–10 1,362 613 1.00 1.0
11–700 1,023 533 1.16 (1.01, 1.33) 1.33 (1.13, 1.56)
Missing 54 26
With mutation 0–10 18 21 1.00 1.00
11–700 12 14 1.00 (0.37, 2.71) 0.99 (0.33, 2.91) 0.59 0.25
Missing 0 0
Lifetime painful or blistering burns to the site of the melanoma
No mutation None 1,310 522 1.00 1.00
Any 945 544 1.45 (1.25, 1.67) 1.49 (1.27, 1.77)
Missing 184 106
With mutation None 13 22 1.00 1.00
Any 11 13 0.69 (0.25, 1.94) 0.57 (0.19, 1.74) 0.09 0.09
Missing 6 0
Abbreviations: CI, confidence interval; MPM, multiple primary melanoma; OR, odds ratio; SPM, single primary melanoma; UVE, erythemal UVR.
1Analyses are adjusted for age, sex, age–sex interaction, center, and ability to tan.
2Multiplicative interaction using categories of sun exposure.
3Multiplicative interaction using continuous values of sun exposure.
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familial melanoma gene, in 3,624 mela-
noma patients from nine centers in four
countries (Berwick et al., 2006; Orlow
et al., 2007), and we have identified the
same patterns of sun exposure in risk for
a second primary melanoma (Kricker
et al., 2007) as are found for incident,
first primary melanomas (Gandini et al.,
2005). We therefore wanted to iden-
tify whether and how these two impor-
tant risk factors—sun exposure and
CDKN2A—might interact to increase
melanoma risk.
We identified incident cases of
melanoma from eight population-based
registries in Australia (New South Wales
and Tasmania), Italy (Piedmont area),
Canada (British Columbia and Ontario),
the United States (New Jersey, North
Carolina, and Orange and San Diego
Counties), and one hospital center in
Michigan, which sees B50% of the
melanoma diagnosed in the state. The
study design and details of the data
collection have been previously pub-
lished (Begg et al., 2006). Briefly, single
primary melanoma (SPM) controls were
people diagnosed with an incident first
invasive primary melanoma within a
defined accrual period of 6 months
during the year 2000, and multiple
primary melanoma (MPM) cases were
people diagnosed with an incident
second- or higher-order invasive or
in situ melanoma during a 3.5-year
period from 1 January 2000. Inclusion
of in situ cases was designed to avoid
exclusion of people who could have
been diagnosed with an invasive subse-
quent primary if the in situ lesion had not
been removed. Participants gave in-
formed consent, donated 4–6 buccal
swabs or blood for DNA extraction,
and completed questionnaires detailing
demographics, phenotypic characteris-
tics, family history of cancer, and lifetime
sun exposure behavior. The study proto-
col was approved by the Institutional
Review Board of each participating
institution. All study procedures adhered
to the Declaration of Helsinki Principles.
Sequencing was conducted for exons 1a,
2, and 3 of the CDKN2A gene, which
code for the p16 and or p14ARF proteins
as described previously (Berwick et al.,
2006; Orlow et al., 2007).
Functional CDKN2A mutations (Orlow
et al., 2007) were identified in 30 of 2,469
individuals with SPMs (1.3%) and in 35
of 1,207 individuals with MPM (2.9%;
Berwick et al., 2006). As we published
previously, those with CDKN2A muta-
tions are significantly younger than those
with wild-type CDKN2A, more likely to
have a family history of melanoma, more
likely to have multiple melanomas, and
more nevi.
We used five measures of sun expo-
sure previously reported by our group
as important risk factors for second
primary melanomas (Kricker et al., 2007):
(1) ambient erythemal UVR exposure
at the age of 10 years—a measure of
early-life sun exposure supported by
migrant studies where the effect of
ambient sun exposure is greatest in
those who migrated before 10–15 years
of age, (2) average annual hours on
sunny holidays, (3) average annual
hours of beach and waterside exposure,
(4) lifetime painful or blistering burns,
and (5) lifetime painful or blistering
burns to the site of the melanoma. The
latter four measures reflect an intermit-
tent pattern of sun exposure, usually
indicated by recreational exposure, the
major form of sun exposure that has
been associated with the development
of melanoma (Armstrong, 1988; Gandi-
ni et al., 2005). Odds ratios were cal-
culated using logistic regression for
unadjusted and adjusted stratified ana-
lyses, controlling for age, sex, study
center, an age–sex interaction, and
ability to tan. Multiplicative interactions
were assessed using cross-product terms.
All statistical analyses were undertaken
using SAS Statistical Packages Version
9.2 (SAS, Cary, NC). All statistical tests
were two sided.
We observed no statistically signifi-
cant multiplicative interactions between
any measure of intermittent sun expo-
sure and mutation ofCDKN2A (Table 1).
The stratified analyses show no statisti-
cally significant differences in effects of
increasing sun exposure between muta-
tion carriers and non-carriers, and the
relative risk estimates are generally
smaller than for the non-carriesrs.
These findings suggest that increas-
ing sun exposure may add little to the
increased risk of melanoma that is
conferred by carriage of a CDKN2A
mutation, and that those with a muta-
tion are at high risk for the development
of melanoma regardless of sun exposure.
The adjusted relative risk of melanoma in
carriers is 4.2 (95% confidence interval
2.4, 7.7), as reported earlier in Berwick
et al. (2006).
Previous efforts to document a
gene–environment interaction among
CDKN2A carriers have reported similar
findings. Consistent with the present
results, Goldstein et al. (1998) did not
find that sun exposure (measured as
sunburns) was a significant risk factor
for melanoma among families with
CDKN2A mutations. Recently, Cust
et al. (2011) reported that CDKN2A
carriers appeared to have the same
cumulative risk of melanoma regardless
of ambient sun exposure, thus suggest-
ing that our observation of risk of
second primary melanoma may be
generalizable to all primary melanoma.
Most studies of CDKN2A have focused
on smaller populations (e.g., Nielsen
et al., 2010) or on familial studies (such
as Goldstein et al., 1998; Bishop et al.,
2002; Cust et al., 2011); GEM is the
largest population-based series to se-
quence CDKN2A among individuals
diagnosed with melanoma. Clearly, as
the prevalence of CDKN2A mutations
is very low, the ability to analyze the
interaction between CDKN2A and solar
exposure in the general population is
necessarily limited, and inferences from
such analyses are uncertain.
In summary, our study provides no
evidence to suggest that the influences
of CDKN2A mutational status and sun
exposure on melanoma risk are related.
In addition, we found little evidence
that sun exposure increases the risk
of melanoma in carriers, although our
sample sizes are too small for a defi-
nitive conclusion on this issue. In the
absence of further evidence, people with
CDKN2A mutations should receive at
least the same sun protection advice
as other people with similar phenotypic
risk factors.
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TO THE EDITOR
Healing of large traumatic soft-tissue
wounds in humans is often associated
with scarring and infection. Medical
management involves initial antisepsis,
hemostasis, control of infection, and
attempts to control scar formation
through surgical intervention. The treat-
ment of microbially contaminated large
soft-tissue wounds remains a medical
challenge.
I wish to call attention to the healing
of deep soft tissues by the bottlenose
dolphin (Indo-Pacific bottlenose dolphins,
Tursiops sp.). Dolphins commonly sus-
tain deep soft-tissue injuries from shark
bites (Celona et al., 2006). About 40%
of bottlenose dolphins surveyed by one
marine station in Australia appeared
to have survived a shark bite, based
on distinguishable surface markings
(Corkeron et al., 1987a). In what man-
ner does a deep wound heal in these
mammals in the sea? Will an apprecia-
tion of the mechanism of repair provide
new insights to those of us involved in
the care of human injuries?
Two case reports are presented that
illustrate the types of injury I am
referring to and the nature of the
recovery process, derived from the
observations and photographs shared
with me by marine biologists caring for
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